Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021

Vaccine. 2022 Jul 30;40(32):4654-4662. doi: 10.1016/j.vaccine.2022.06.007. Epub 2022 Jun 8.

Abstract

Background: There is a long history in Japan of public concerns about vaccine adverse events. Few studies have assessed how mobile messenger apps affect COVID-19 vaccine hesitancy.

Methods: Corowa-kun, a free chatbot, was created on February 6, 2021 in LINE, the most popular messenger app in Japan. Corowa-kun provides instant, automated answers to 70 frequently asked COVID-19 vaccine questions. A cross-sectional survey with 21 questions was performed within Corowa-kun during April 5-12, 2021.

Results: A total of 59,676 persons used Corowa-kun during February-April 2021. Of them, 10,192 users (17%) participated in the survey. Median age was 55 years (range 16-97), and most were female (74%). COVID-19 vaccine hesitancy reported by survey respondents decreased from 41% to 20% after using Corowa-kun. Of the 20% who remained hesitant, 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16-34 (odds ratio [OR] = 3.7; 95% confidential interval [CI]: 3.0-4.6, compared to age ≥ 65), female sex (OR = 2.4; Cl: 2.1-2.8), and history of a previous vaccine side-effect (OR = 2.5; Cl: 2.2-2.9). Being a physician (OR = 0.2; Cl: 0.1-0.4) and having received a flu vaccine the prior season (OR = 0.4; Cl: 0.3-0.4) were protective.

Conclusions: A substantial number of people used the chabot in a short period. Mobile messenger apps could be leveraged to provide accurate vaccine information and to investigate vaccine intention and risk factors for vaccine hesitancy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Female
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Mobile Applications*
  • Parents
  • Patient Acceptance of Health Care
  • Vaccination
  • Young Adult

Substances

  • COVID-19 Vaccines